

Baxter International Inc.
Key Product Line Sales -- US/International
Periods Ending March 31, 2007 and 2006
(unaudited)
(\$ in millions)

	Q1 2007			Q1 2006 ¹			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants ²	\$179	\$209	\$388	\$161	\$174	\$335	11%	20%	16%
Plasma Proteins ³	88	137	225	67	125	192	31%	10%	17%
Antibody Therapy	159	63	222	139	44	183	14%	43%	21%
Regenerative Medicine ⁴	43	39	82	39	30	69	10%	30%	19%
Other ⁵	15	140	155	12	85	97	25%	65%	60%
Total BioScience⁶	\$484	\$588	\$1,072	\$418	\$458	\$876	16%	28%	22%
Medication Delivery									
IV Therapies ⁷	\$101	\$219	\$320	\$104	\$200	\$304	(3%)	10%	5%
Global Injectables ⁸	227	134	361	225	128	353	1%	5%	2%
Infusion Systems	122	87	209	124	71	195	(2%)	23%	7%
Anesthesia ⁹	60	29	89	33	21	54	82%	38%	65%
Other ¹⁰	5	6	11	5	5	10	0%	20%	10%
Total Medication Delivery	\$515	\$475	\$990	\$491	\$425	\$916	5%	12%	8%
Renal									
PD Therapy	\$69	\$350	\$419	\$66	\$322	\$388	5%	9%	8%
HD Therapy	28	78	106	28	77	105	0%	1%	1%
Total Renal	\$97	\$428	\$525	\$94	\$399	\$493	3%	7%	6%
Baxter excluding Transfusion Therapies	\$1,096	\$1,491	\$2,587	\$1,003	\$1,282	\$2,285	9%	16%	13%
Transfusion Therapies¹¹	\$43	\$45	\$88	\$56	\$68	\$124	(23%)	(34%)	(29%)
TOTAL BAXTER	\$1,139	\$1,536	\$2,675	\$1,059	\$1,350	\$2,409	8%	14%	11%

¹ Prior year sales data has been reclassified to reflect the changes that are described in notes 2, 5, 6, 8, 9 and 11 below.

² Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE). Sales of recombinant FIX (BenefIX) were previously reported in Recombinants and are now reported in Other, as detailed below.

³ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, and certain other plasma-based products.

⁴ Previously referred to as BioSurgery.

⁵ Principally includes vaccines and sales of plasma to third parties, and recombinant FIX (BenefIX). Sales of recombinant FIX (BenefIX) were previously reported in Recombinants.

⁶ BioScience sales have been reclassified to reflect the change described in Note 11.

⁷ Principally includes intravenous solutions and nutritional products.

⁸ Principally includes sales related to pharma partnering business, enhanced packaging, premix drugs and generic injectables. Generic injectables were previously reported in Anesthesia.

⁹ Principally includes proprietary inhaled anesthetics and other anesthesia products. Sales of generic injectables were previously reported in Anesthesia and are now reported in Global Injectables.

¹⁰ Principally includes other hospital-distributed products.

¹¹ Sales of Transfusion Therapies (TT) products were previously reported in BioScience. Due to Baxter's expected significant continuing cash flows associated with this business, Baxter continued to include the results of operations of TT in the company's results of operations through the February 28, 2007 sale date. The amounts reported above reflect sales of TT products until the completion of the sale of the TT business, as well as revenues associated with manufacturing, distribution and other services provided by the company to the buyer post-divestiture.